Current Opinion in Pediatrics,
Journal Year:
2024,
Volume and Issue:
36(2), P. 144 - 149
Published: Jan. 3, 2024
Purpose
of
review
This
is
structured
to
update
clinicians
on
the
epidemiology,
antibiotic
treatment,
and
prevention
pediatric
bacterial
pneumonia.
The
provides
information
regarding
current
research
management
for
pneumonia
newest
immunization
recommendations
prevent
pneumococcal
other
respiratory
infections.
Recent
findings
recommended
length
therapy
has
been
discrepant
between
low-income
high-income
countries.
Recently,
randomized
controlled
trials
conducted
in
countries
provided
evidence
support
a
short
course
(3–5
days)
uncomplicated
otherwise
healthy
children.
negative
impact
inaccurate
penicillin
allergy
labels
children
with
emphasized
importance
prompt
de-labeling.
Newer
vaccines
are
expected
have
significant
rates.
Summary
Pediatric
an
important
contributor
childhood
morbidity
mortality.
A
seems
be
sufficient
outpatient
pneumonia;
however,
more
studies
required
inpatient
setting.
Future
will
inform
recently
introduced
syncytial
virus
epidemiology
ABSTRACT
Penicillins
are
the
most
frequently
prescribed
class
of
medications
worldwide
and
first‐line
antibiotic
choice
for
bacterial
infections.
They
also
commonly
labelled
as
culprit
drug
‘allergy’;
leading
to
obligatory
use
second‐line
antibiotics,
suboptimal
therapy
increased
antimicrobial
resistance.
However,
majority
reported
penicillin
‘allergy’
labels
found
be
incorrect
after
allergy
testing,
emphasising
importance
proper
testing
evaluation.
Penicillin
skin
(PST)
remains
an
important
component
diagnosis;
however,
its
practice
policies
significantly
differ
across
world.
Inappropriate
non‐evidence‐based
PST
practices
can
lead
consequences
associated
with
mislabelling.
Even
within
different
regions
China,
a
population
exceeding
1.4
billion,
there
marked
differences
in
implementation,
execution
interpretation
PST.
This
review
aims
examine
between
Mainland
Hong
Kong
rest
We
critically
analyse
current
‘pre‐emptive’
which
has
significant
false‐positive
rate
high
levels
Non‐evidence‐based
further
compound
rates
indiscriminatory
postulate
that
inappropriate
may
exacerbate
mislabelling
allergy,
unnecessary
overuse
increasing
resistance
healthcare
costs.
advocate
more
collaborative
research
improve
contemporary
workflow
diagnosis,
reduce
promote
dissemination
evidence‐based
methods
diagnosis.
Current Opinion in Pediatrics,
Journal Year:
2024,
Volume and Issue:
36(2), P. 144 - 149
Published: Jan. 3, 2024
Purpose
of
review
This
is
structured
to
update
clinicians
on
the
epidemiology,
antibiotic
treatment,
and
prevention
pediatric
bacterial
pneumonia.
The
provides
information
regarding
current
research
management
for
pneumonia
newest
immunization
recommendations
prevent
pneumococcal
other
respiratory
infections.
Recent
findings
recommended
length
therapy
has
been
discrepant
between
low-income
high-income
countries.
Recently,
randomized
controlled
trials
conducted
in
countries
provided
evidence
support
a
short
course
(3–5
days)
uncomplicated
otherwise
healthy
children.
negative
impact
inaccurate
penicillin
allergy
labels
children
with
emphasized
importance
prompt
de-labeling.
Newer
vaccines
are
expected
have
significant
rates.
Summary
Pediatric
an
important
contributor
childhood
morbidity
mortality.
A
seems
be
sufficient
outpatient
pneumonia;
however,
more
studies
required
inpatient
setting.
Future
will
inform
recently
introduced
syncytial
virus
epidemiology
